Key factors driving this growth include the adoption of innovative technologies in small molecule drug development, the expansion of pharmaceutical pipelines focused on small molecule therapies, and the increasing reliance on CDMOs for their cost-efficiency and specialized services. Regulatory support for streamlined drug development and manufacturing processes, along with CDMOs scaling up their production capacities to meet growing industry needs, also contribute significantly to market expansion. For pharmaceutical companies, innovation and ease of access to clinical solutions remain essential.Specialty pharmaceutical firms and small-scale players are playing a pivotal role in meeting these critical industry demands. Many CDMOs are adopting the “one-stop-shop” model, offering comprehensive services ranging from active pharmaceutical ingredient (API) production to dosage formulation, and from early-stage development to final commercialization. This approach requires CDMOs to possess a broad array of enabling technologies and advanced handling capabilities tailored to address specific challenges. The presence of a considerable number of CDMOs providing end-to-end services globally is expected to further propel market growth. Additionally, the rising prevalence of chronic diseases supports the increasing demand for innovative small molecule-based therapies, consequently boosting the need for CDMO services.
Get a preview of the latest developments in the Global Small Molecule CDMO Market! Download your FREE sample PDF Download your FREE sample PDF today and explore key data and trends
Small Molecule CDMO Market Report Highlights
API Segment: In 2023, this segment held the largest share of 62.3%, driven by increased R&D in novel drug development and robust pipelines maintained by major pharmaceutical companies.
Generics Segment: Expected to register the fastest CAGR of 8.0% from 2024 to 2030. This growth is fueled by the high prevalence of conditions such as cancer, diabetes, and cardiovascular diseases, along with government initiatives aimed at expanding access to generic medications.
Oncology Segment: Accounted for the largest revenue share at 35.1% in 2023. The segment’s growth is attributed to the rising global cancer incidence, supportive government reimbursement policies, and increased funding for developing small molecule oncology drugs.
Asia Pacific Region: Projected to record the highest CAGR of 7.7% from 2024 to 2030. The region, led by China and India, benefits from lower manufacturing costs and favorable regulatory conditions, making it a key market for CDMO services.
Key Players in the Small Molecule CDMO Market
Lonza
Catalent, Inc
Thermo Fisher Scientific Inc.
Cambrex Corporation
Bellen Chemistry
Siegfried Holding AG
Recipharm AB
Eurofins Scientific
Aurigene Pharmaceutical Services Ltd.
CordenPharma International
Gather more insights about the market drivers, restrains and growth of the Small Molecule CDMO Market